Loor F - Search Results

1

Expression of P-glycoprotein on normal lymphocytes: enhancement of the doxorubicin-sensitivity of concanavalin A-responding mouse spleen cells by P-glycoprotein blockers.

Pourtier-Manzanedo A, Didier A, Loor F. Pourtier-Manzanedo A, et al. Among authors: loor f. Oncol Res. 1992;4(11-12):473-80. Oncol Res. 1992. PMID: 1363723

2

Lymphotoxicity and myelotoxicity of doxorubicin and SDZ PSC 833 combined chemotherapies for normal mice.

Pourtier-Manzanedo A, Didier A, Froidevaux S, Loor F. Pourtier-Manzanedo A, et al. Among authors: loor f. Toxicology. 1995 May 23;99(3):207-17. doi: 10.1016/0300-483x(95)03056-l. Toxicology. 1995. PMID: 7610467

3

Detection of P-glycoprotein expression by tumoral cells with NBDL-CsA, a fluorescent derivative of cyclosporin A.

Didier A, Tiberghien F, Wenger R, Loor F. Didier A, et al. Among authors: loor f. Anticancer Drugs. 1996 May;7(3):257-65. doi: 10.1097/00001813-199605000-00004. Anticancer Drugs. 1996. PMID: 8791998

4

Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers.

Didier A, Wenger J, Loor F. Didier A, et al. Among authors: loor f. Anticancer Drugs. 1995 Oct;6(5):669-80. doi: 10.1097/00001813-199510000-00006. Anticancer Drugs. 1995. PMID: 8845477

5

The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor.

Didier A, Loor F. Didier A, et al. Among authors: loor f. Anticancer Drugs. 1996 Sep;7(7):745-51. doi: 10.1097/00001813-199609000-00005. Anticancer Drugs. 1996. PMID: 8949985

6

SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells.

Pourtier-Manzanedo A, Didier AD, Muller CD, Loor F. Pourtier-Manzanedo A, et al. Among authors: loor f. Anticancer Drugs. 1992 Aug;3(4):419-25. doi: 10.1097/00001813-199208000-00017. Anticancer Drugs. 1992. PMID: 1421439

7

Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors.

Didier AD, Loor F. Didier AD, et al. Among authors: loor f. Int J Cancer. 1995 Oct 9;63(2):263-7. doi: 10.1002/ijc.2910630220. Int J Cancer. 1995. PMID: 7591215

8

Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter.

Loor F, Tiberghien F, Wenandy T, Didier A, Traber R. Loor F, et al. J Med Chem. 2002 Oct 10;45(21):4598-612. doi: 10.1021/jm0109863. J Med Chem. 2002. PMID: 12361387

9

Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter.

Tiberghien F, Kurome T, Takesako K, Didier A, Wenandy T, Loor F. Tiberghien F, et al. Among authors: loor f. J Med Chem. 2000 Jun 29;43(13):2547-56. doi: 10.1021/jm990955w. J Med Chem. 2000. PMID: 10891114

10

In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.

Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F. Boesch D, et al. Among authors: loor f. Cancer Res. 1991 Aug 15;51(16):4226-33. Cancer Res. 1991. PMID: 1678313

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

126 results

Search Page

Filters